Francesco V.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
- Phase III Trial Comparing FOLFIRI Plus Cetuximab Versus Bevacizumab in First-Line Treatment of mCRC with RAS/BRAF Wild-Type Tissue and Mutated Liquid Biopsy
- Phase 3 Study of BAY 2927088 vs. Standard of Care in HER2-Mutant Advanced NSCLC
Data & Insights
Has run more than one trial at 74 of 289 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in treating advanced forms of non-small cell lung cancer (NSCLC), with particular focus on specific genetic mutations including HER2 (ERBB2) and KRAS G12C variations.
- Advanced NSCLC with HER2 mutations
- KRAS G12C-positive metastatic NSCLC
- Targeted therapy approaches
Their research encompasses novel therapeutic strategies for patients with advanced lung cancer manifestations.
Gastrointestinal Oncology
The investigator focuses on treating advanced biliary tract cancers and metastatic colorectal cancer (mCRC), exploring innovative combination therapy approaches.
- Advanced biliary tract cancers
- Metastatic colorectal cancer
- First-line treatment strategies
Their work includes evaluation of immunotherapy combinations and targeted treatments for gastrointestinal malignancies.
Precision Medicine
The investigator's research encompasses molecular-guided therapy approaches, particularly focusing on RAS/BRAF mutations and their impact on treatment selection.
- Liquid biopsy applications
- Biomarker-driven treatments
- Targeted therapy optimization
Their work integrates molecular testing strategies to guide personalized treatment decisions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.